Featured Research

from universities, journals, and other organizations

Severe morning sickness patients get relief from anti-seizure drug

Date:
December 7, 2012
Source:
University at Buffalo
Summary:
Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.

Related Articles


Thomas Guttuso Jr., MD, assistant professor of neurology in the UB School of Medicine and Biomedical Sciences, has been studying the drug gabapentin, an anti-seizure and anti-pain drug that he previously had studied in cancer patients receiving chemotherapy.

"I became interested in this drug for hyperemesis gravidarum (an extreme form of morning sickness) because I saw how effective it appeared to be in treating chemotherapy-induced nausea and vomiting in patients who had failed treatment with conventional anti-emetics," says Guttuso. Anti-emetics are drugs currently approved for treating nausea and vomiting.

In 2010, he published in the journal Early Human Development the results of an open-label pilot study that enrolled seven women from Western New York examining the drug's safety, tolerability and effectiveness in treating hyperemesis gravidarum.

"It was really exciting to see how quickly the women responded," says Guttuso. None of the women had seen any improvement on any other anti-emetic medications they had tried.

"But when they started with gabapentin, all of them showed a dramatic improvement," he says. "Within two hours of taking the first pill, most of the patients were feeling much better and several were able to start eating and drinking again. It was a pretty amazing thing to see.

"The study showed that after two weeks of gabapentin therapy, the seven women experienced an average 80 percent reduction in their nausea and a 94 percent reduction in their vomiting and near normal levels of eating and drinking," Guttuso says. After this study was published, Guttuso knows of five more women with hyperemesis gravidarum that tried gabapentin and all experienced excellent relief.

The women needed to take gabapentin on average until about half way through their pregnancies before they could stop it without recurrent nausea and vomiting.

One of the potential concerns with gabapentin was that two of the babies born to patients in the UB study were found to have congenital defects. As a result, the Food and Drug Administration placed the study on clinical hold in April 2011 until further safety data was available on the use of gabapentin during pregnancy.

By May 2012 several pregnancy registries and other studies had reported that the rate of congenital defects among a total of 258 infants born to women taking gabapentin early in their pregnancies was about the same as the rate of congenital defects in the general population. After reviewing these findings, the FDA removed the clinical hold allowing Guttuso to resume his research on the effects of gabapentin on hyperemesis gravidarum. Although the results of the small pilot study were very encouraging, Guttuso emphasizes that a placebo-controlled study among many more patients needs to be conducted in order to know if gabapentin truly is effective for hyperemesis gravidarum. "The evidence right now is still very preliminary," he states.

Early next year, Guttuso plans to submit a new grant proposal to the National Institutes of Health in order to support such a study with enrolling sites both at UB and at the University of Rochester. Guttuso is hopeful that the study will be funded.

"This is a study that really needs to be done because currently there are no effective treatments for hyperemesis gravidarum," Guttuso says. "Women end up having to keep going back to the hospital for intravenous fluids because of dehydration from their persistent nausea and vomiting."

Guttuso is a Western New York neurologist and UB professor whose practice focuses primarily on patients with movement disorders such as Parkinson's disease. He originally became interested in gabapentin when he accidentally discovered that it appeared to be effective in treating hot flashes in postmenopausal women. Soon thereafter, another patient with breast cancer undergoing chemotherapy informed him that gabapentin appeared to fully resolve her chemotherapy-induced nausea and vomiting.

After observing the marked improvements in nausea and vomiting that many cancer patients experienced from gabapentin, he thought that it should be tried with patients suffering from hyperemesis gravidarum. He then teamed up with several Buffalo obstetricians to do the pilot study on pregnant women.

"I think a lot of people don't appreciate just how sick and disabled these women can be," Guttuso says. He notes that 15 percent of women with this condition end up having abortions even though they really want to have children.

"Some of the most severely affected end up having abortions because they have no hope of getting better," he says. "Ending the pregnancy is currently the only effective treatment for hyperemesis gravidarum. These women are so sick. They often retch every 15 to 30 minutes and it can go on all day and often at night as well."

Two of the women in Guttuso's small pilot study were planning to have abortions. One of them was scheduled for one the next day out of desperation. Once she went on gabapentin, her symptoms abated and she was able to continue with her pregnancy to term. Since then, she has had a second healthy child while taking gabapentin throughout her pregnancy, during which she had only mild and rare nausea and vomiting.

"I think this research has great potential to provide relief to many women suffering with hyperemesis gravidarum," says Guttuso.


Story Source:

The above story is based on materials provided by University at Buffalo. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas Guttuso, Luther K. Robinson, Kofi S. Amankwah. Gabapentin use in hyperemesis gravidarum: A pilot study. Early Human Development, 2010; 86 (1): 65 DOI: 10.1016/j.earlhumdev.2009.11.003

Cite This Page:

University at Buffalo. "Severe morning sickness patients get relief from anti-seizure drug." ScienceDaily. ScienceDaily, 7 December 2012. <www.sciencedaily.com/releases/2012/12/121207132801.htm>.
University at Buffalo. (2012, December 7). Severe morning sickness patients get relief from anti-seizure drug. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2012/12/121207132801.htm
University at Buffalo. "Severe morning sickness patients get relief from anti-seizure drug." ScienceDaily. www.sciencedaily.com/releases/2012/12/121207132801.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins